eクリニカルソリューション市場製品別（電子データ取得・臨床データ管理システム、臨床試験管理システム、無作為化・試験供給管理、電子臨床アウトカム評価、電子証跡マスターファイル、その他）、提供形態別（ウェブホスティング、オンプレミス、クラウドベース）、臨床試験フェーズ別（フェーズ1、フェーズ2、フェーズ3、フェーズ4）、エンドユーザー別（医薬品・バイオ医薬品会社、受託研究組織、その他）。世界の機会分析および産業予測、2021-2031年

eClinical solutions Market By Product (Electronic Data Capture and Clinical Data Management Systems, Clinical Trial Management Systems, Randomization and Trial Supply Management, Electronic Clinical Outcome Assessment, Electronic Trail Master Files, Others), By Delivery Mode (Web-hosted, On-premise, Cloud-based), By Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV), By End User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

eClinicalソリューションの世界市場は、2021年に68億1617万ドルとなり、2031年には215億295万ドルに達し、2022年から2031年にかけて年平均成長率12.2％で成長すると予測されます。 eClinicalソリューションは、... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年7月31日	US$6,090 シングルユーザライセンスライセンス・価格情報注文方法はこちら	358	英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

eClinicalソリューションの世界市場は、2021年に68億1617万ドルとなり、2031年には215億295万ドルに達し、2022年から2031年にかけて年平均成長率12.2％で成長すると予測されます。
eClinicalソリューションは、臨床試験中に生成されるデータの効果的な管理、統合に使用されるソフトウェアです。臨床試験のポートフォリオを効果的に計画、管理、追跡し、洞察を得るためのツール一式を提供します。eClinicalソリューション市場の成長を促す主な要因は、タイムサイクルの短縮、データの重複の削減、データの選別と統合のために臨床試験実施チームが行う追加的な作業です。

また、eClinicalソリューションは、ソフトウェア自体でデータを分類・統合するため、意思決定を加速させることができます。これは市場の重要なトレンドであり、予測期間中に市場の成長を促進すると予想されます。これらのソリューションは、人口統計グラフ、マッピング、包括的な分析を作成し、臨床および運用上の質問に迅速かつ正確に回答します。このように、データの問題を集中管理することで、エラーが早く特定され、意思決定プロセスが加速されます。さらに、技術の進歩の著しい急増は、紙の作業に多くの時間がかかるため、膨大なデータを管理することは、個々の不満になるように、この市場の1つの主要な要因である。先進的な技術ソリューションを利用することで、臨床試験を実施するチームにとってデータ管理が容易になります。また、臨床試験数の増加により、新興国市場がeClinicalソリューションの利用拡大の拠点となっています。低料金でリソースを入手でき、医薬品開発に関する規制政策も緩やかなため、市場関係者には新興国での事業拡大の機会が多くあります。

データの増強、より良い医療サービスのための政府の取り組みが、新興市場における市場成長を後押ししています。しかし、eClinicalソリューションは、高い初期資本コストと定期的なメンテナンスの試みが必要であり、市場の成長を阻害しています。eClinicalソリューション市場は、製品、デリバリーモード、臨床試験、エンドユーザー、および地域に基づいて区分されます。製品別では、電子データ収集（EDC）＆臨床データ管理システム（CDMS）、臨床試験管理システム（CTMS）、無作為化＆治験供給管理（RTMS）、電子臨床結果評価（eCOA）、電子試験マスターファイル（eTMF）、その他に分類される。

提供形態によって、市場はウェブホスティング型、オンプレミス型、クラウド型に区分されます。臨床試験の種類によって、市場は第I相、第II相、第III相、第IV相に区分されます。エンドユーザー別に見ると、製薬・バイオ医薬品企業、医薬品開発業務受託機関、その他に分類されます。地域別では、北米、欧州、アジア太平洋、中南米・中東・アフリカ（LAMEA）にわたって分析されています。

本レポートで紹介する主なプレイヤーは、Oracle Corporation、Parexel International Corporation（Calyx）、DataTrak International, Inc.、Dassault Systèmes（Medidata Solution, Inc）、Clario、Signant Health（CRF Health Inc）、eClinical Solutions, Inc、IBM Watson Health、Adparra, Inc（Bio-Optronics, Inc）、MaxisIT Inc、Anju Software, Inc.で、主な参加者は、以下の通りです。Veeva Systems、Saama Technologies, Inc.、Medrio, Inc.、Castor EDC、Mednet、Business Systems Integration AG。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2031年までのeClinicalソリューション市場分析の市場セグメント、現在のトレンド、予測、ダイナミクスを定量的に分析し、eClinicalソリューション市場の優勢な機会を特定するものです。
●市場調査は、主要な推進要因、抑制要因、機会に関連する情報とともに提供されます。
ポーターのファイブフォース分析により、買い手と供給者の能力を明らかにし、ステークホルダーが利益志向のビジネス決定を下し、供給者と買い手のネットワークを強化できるようにします。
eClinicalソリューション市場のセグメンテーションの詳細な分析は、市場機会を決定するのに役立ちます。
電子臨床ソリューション市場の詳細な分析は、市場機会を決定するのに役立ちます。
市場プレイヤーのポジショニングは、ベンチマークを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界別の電子臨床ソリューションの市場動向、キープレイヤー、市場セグメント、応用分野、市場成長戦略などの分析が含まれています。

主な市場セグメント
提供形態別
ウェブホスト型
オンプレミス
クラウドベース
臨床試験フェーズ別
フェーズI
フェーズII
フェーズIII
フェーズIV
製品別
臨床試験管理システム
無作為化および治験薬供給管理
電子的な臨床結果評価
電子治験マスターファイル
その他
電子データ収集および臨床データ管理システム
エンドユーザー別
製薬会社およびバイオ医薬品会社
受託研究機関
その他

地域別
北米
米国
カナダ
メキシコ
欧州
ドイツ
フランス
イギリス
イタリア
スペイン
その他の地域
アジア・パシフィック
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
LAMEAの残りの地域

主な市場関係者
アドバラは、バイオオプトロニクス社（Bio Optronics, Inc.）
アンジュ・ソフトウェア
○ ビジネスシステムインテグレーションAG
キャスターEDC
○ クラリオ
○ Dassault Systemes (Medidata Solution, Inc.)
○ DataTrak International, Inc.
○ eClinical Solutions, Inc.
○ IBM ワトソンヘルス
株式会社マキシスアイティー
メドネット・ソリューションズ
メドリオ株式会社
パレクセル・インターナショナル・コーポレーション（キャリックス）
サーマ・テクノロジーズ
シグナント・ヘルス社（CRF Health Inc.）
○ ヴィーヴァ・システムズ
オラクル株式会社

ページTOPに戻る

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ECLINICAL SOLUTIONS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Electronic Data Capture and Clinical Data Management Systems
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Clinical Trial Management Systems
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Randomization and Trial Supply Management
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Electronic Clinical Outcome Assessment
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Electronic Trail Master Files
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Others
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
CHAPTER 5: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE
5.1 Overview
5.1.1 Market size and forecast
5.2 Web-hosted
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 On-premise
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Cloud-based
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
6.1 Overview
6.1.1 Market size and forecast
6.2 Phase I
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Phase II
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Phase III
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Phase IV
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
CHAPTER 7: ECLINICAL SOLUTIONS MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Pharmaceutical and Biopharmaceutical Companies
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 Contract Research Organizations
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Others
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country
CHAPTER 8: ECLINICAL SOLUTIONS MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Product
8.2.3 North America Market size and forecast, by Delivery Mode
8.2.4 North America Market size and forecast, by Clinical Trial Phase
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Market size and forecast, by Product
8.2.6.1.2 Market size and forecast, by Delivery Mode
8.2.6.1.3 Market size and forecast, by Clinical Trial Phase
8.2.6.1.4 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Market size and forecast, by Product
8.2.6.2.2 Market size and forecast, by Delivery Mode
8.2.6.2.3 Market size and forecast, by Clinical Trial Phase
8.2.6.2.4 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Market size and forecast, by Product
8.2.6.3.2 Market size and forecast, by Delivery Mode
8.2.6.3.3 Market size and forecast, by Clinical Trial Phase
8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Product
8.3.3 Europe Market size and forecast, by Delivery Mode
8.3.4 Europe Market size and forecast, by Clinical Trial Phase
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Market size and forecast, by Product
8.3.6.1.2 Market size and forecast, by Delivery Mode
8.3.6.1.3 Market size and forecast, by Clinical Trial Phase
8.3.6.1.4 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Market size and forecast, by Product
8.3.6.2.2 Market size and forecast, by Delivery Mode
8.3.6.2.3 Market size and forecast, by Clinical Trial Phase
8.3.6.2.4 Market size and forecast, by End User
8.3.6.3 U.K.
8.3.6.3.1 Market size and forecast, by Product
8.3.6.3.2 Market size and forecast, by Delivery Mode
8.3.6.3.3 Market size and forecast, by Clinical Trial Phase
8.3.6.3.4 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Market size and forecast, by Product
8.3.6.4.2 Market size and forecast, by Delivery Mode
8.3.6.4.3 Market size and forecast, by Clinical Trial Phase
8.3.6.4.4 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Market size and forecast, by Product
8.3.6.5.2 Market size and forecast, by Delivery Mode
8.3.6.5.3 Market size and forecast, by Clinical Trial Phase
8.3.6.5.4 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Market size and forecast, by Product
8.3.6.6.2 Market size and forecast, by Delivery Mode
8.3.6.6.3 Market size and forecast, by Clinical Trial Phase
8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Product
8.4.3 Asia-Pacific Market size and forecast, by Delivery Mode
8.4.4 Asia-Pacific Market size and forecast, by Clinical Trial Phase
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 Japan
8.4.6.1.1 Market size and forecast, by Product
8.4.6.1.2 Market size and forecast, by Delivery Mode
8.4.6.1.3 Market size and forecast, by Clinical Trial Phase
8.4.6.1.4 Market size and forecast, by End User
8.4.6.2 China
8.4.6.2.1 Market size and forecast, by Product
8.4.6.2.2 Market size and forecast, by Delivery Mode
8.4.6.2.3 Market size and forecast, by Clinical Trial Phase
8.4.6.2.4 Market size and forecast, by End User
8.4.6.3 India
8.4.6.3.1 Market size and forecast, by Product
8.4.6.3.2 Market size and forecast, by Delivery Mode
8.4.6.3.3 Market size and forecast, by Clinical Trial Phase
8.4.6.3.4 Market size and forecast, by End User
8.4.6.4 Australia
8.4.6.4.1 Market size and forecast, by Product
8.4.6.4.2 Market size and forecast, by Delivery Mode
8.4.6.4.3 Market size and forecast, by Clinical Trial Phase
8.4.6.4.4 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Market size and forecast, by Product
8.4.6.5.2 Market size and forecast, by Delivery Mode
8.4.6.5.3 Market size and forecast, by Clinical Trial Phase
8.4.6.5.4 Market size and forecast, by End User
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Market size and forecast, by Product
8.4.6.6.2 Market size and forecast, by Delivery Mode
8.4.6.6.3 Market size and forecast, by Clinical Trial Phase
8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Product
8.5.3 LAMEA Market size and forecast, by Delivery Mode
8.5.4 LAMEA Market size and forecast, by Clinical Trial Phase
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Market size and forecast, by Product
8.5.6.1.2 Market size and forecast, by Delivery Mode
8.5.6.1.3 Market size and forecast, by Clinical Trial Phase
8.5.6.1.4 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Market size and forecast, by Product
8.5.6.2.2 Market size and forecast, by Delivery Mode
8.5.6.2.3 Market size and forecast, by Clinical Trial Phase
8.5.6.2.4 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Market size and forecast, by Product
8.5.6.3.2 Market size and forecast, by Delivery Mode
8.5.6.3.3 Market size and forecast, by Clinical Trial Phase
8.5.6.3.4 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Market size and forecast, by Product
8.5.6.4.2 Market size and forecast, by Delivery Mode
8.5.6.4.3 Market size and forecast, by Clinical Trial Phase
8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 Advarra, Inc. (Bio Optronics, Inc.)
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 Anju Software, Inc.
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 Business Systems Integration AG
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Castor EDC
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Clario
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 Dassault Systemes (Medidata Solution, Inc.)
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 DataTrak International, Inc.
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 eClinical Solutions, Inc.
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 IBM Watson Health
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 MaxisIT Inc.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments
10.11 MedNet Solutions
10.11.1 Company overview
10.11.2 Company snapshot
10.11.3 Operating business segments
10.11.4 Product portfolio
10.11.5 Business performance
10.11.6 Key strategic moves and developments
10.12 Medrio, Inc.
10.12.1 Company overview
10.12.2 Company snapshot
10.12.3 Operating business segments
10.12.4 Product portfolio
10.12.5 Business performance
10.12.6 Key strategic moves and developments
10.13 Parexel International Corporation (Calyx)
10.13.1 Company overview
10.13.2 Company snapshot
10.13.3 Operating business segments
10.13.4 Product portfolio
10.13.5 Business performance
10.13.6 Key strategic moves and developments
10.14 Saama Technologies, Inc.
10.14.1 Company overview
10.14.2 Company snapshot
10.14.3 Operating business segments
10.14.4 Product portfolio
10.14.5 Business performance
10.14.6 Key strategic moves and developments
10.15 Signant Health (CRF Health Inc.)
10.15.1 Company overview
10.15.2 Company snapshot
10.15.3 Operating business segments
10.15.4 Product portfolio
10.15.5 Business performance
10.15.6 Key strategic moves and developments
10.16 veeva systems
10.16.1 Company overview
10.16.2 Company snapshot
10.16.3 Operating business segments
10.16.4 Product portfolio
10.16.5 Business performance
10.16.6 Key strategic moves and developments
10.17 Oracle Corporation
10.17.1 Company overview
10.17.2 Company snapshot
10.17.3 Operating business segments
10.17.4 Product portfolio
10.17.5 Business performance
10.17.6 Key strategic moves and developments

ページTOPに戻る

Table of Contents

Summary

The global eClinical solutions market was valued at $6,816.17 million in 2021, and is estimated to reach $21,502.95 million by 2031, growing at a CAGR of 12.2% from 2022 to 2031.
eClinical solutions are software, which are used for effective management, and integration of data generated during clinical trials. It offers set of tools to effectively plan, manage, track clinical study portfolio and create insights. The major factors that drive the growth of the eClinical solutions market are decrease in time cycle, reduction in data duplication, and additional efforts taken by team carrying out clinical trial for sorting and integrating the data.

In addition, eClinical solutions accelerates decision making as data is sorted and integrated by the software itself. It is a key trend of the market, which is expected to fuel the growth of the market during the forecast period. These solutions creates the demographic charts, mapping and comprehensive analytics that answer clinical and operational questions with speed and accuracy. Thus by centralizing data issues, errors are identified sooner and decision making process gets accelerated. Furthermore, significant surge in technological advancement is also one leading factors of this market as paper work takes much time, thus, managing enormous data makes individual frustrated. By using advanced technological solutions it becomes easier to manage data for the team carrying out clinical trials. Moreover, emerging markets are becoming a hub for the growth of eClinical solutions utilization owing to rise in the number of clinical trials. There are lot of opportunities for the market players to expand their business across developing economies due to availability of resources at lower rate and less regulatory policies for drug development.

Augmentation of data, government initiatives for making better healthcare services assists the market growth in emerging markets. However, eClinical solutions required high initial capital cost and regular maintenance attempts, which impede the market growth. The eClinical solutions market is segmented on the basis of product, delivery mode, clinical trials, end user, and region. On the basis of product, the market is categorized into electronic data capture (EDC) &clinical data management systems (CDMS), clinical trial management systems (CTMS), randomization & trial supply management (RTMS), electronic clinical outcome assessment (eCOA), electronic trial master file (eTMF), and others.

On the basis of delivery mode, the market is segmented as web–hosted, on–premise, and cloud-based. On the basis of clinical trials, the market is segmented as Phase I, Phase II, Phase III, and Phase IV. On the basis of end users, the market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are Oracle Corporation, Parexel International Corporation (Calyx), DataTrak International, Inc., Dassault Systèmes (Medidata Solution, Inc.), Clario, Signant Health (CRF Health Inc.), eClinical Solutions, Inc., IBM Watson Health, Advarra, Inc. (Bio-Optronics, Inc.), MaxisIT Inc., Anju Software, Inc. Veeva Systems, Saama Technologies, Inc., Medrio, Inc., Castor EDC, Mednet, and Business Systems Integration AG.

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the eClinical solutions market analysis from 2022 to 2031 to identify the prevailing eClinical solutions market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the eClinical solutions market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global eClinical solutions market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments
By Delivery Mode
● Web-hosted
● On-premise
● Cloud-based
By Clinical Trial Phase
● Phase I
● Phase II
● Phase III
● Phase IV
By Product
● Clinical Trial Management Systems
● Randomization and Trial Supply Management
● Electronic Clinical Outcome Assessment
● Electronic Trail Master Files
● Others
● Electronic Data Capture and Clinical Data Management Systems
By End User
● Pharmaceutical and Biopharmaceutical Companies
● Contract Research Organizations
● Others

By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ U.K.
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA

● Key Market Players
○ Advarra, Inc. (Bio Optronics, Inc.)
○ Anju Software, Inc.
○ Business Systems Integration AG
○ Castor EDC
○ Clario
○ Dassault Systemes (Medidata Solution, Inc.)
○ DataTrak International, Inc.
○ eClinical Solutions, Inc.
○ IBM Watson Health
○ MaxisIT Inc.
○ MedNet Solutions
○ Medrio, Inc.
○ Parexel International Corporation (Calyx)
○ Saama Technologies, Inc.
○ Signant Health (CRF Health Inc.)
○ veeva systems
○ Oracle Corporation

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（clinical trial）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（clinical trial）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?